uniQure N.V.

NASDAQ:QURE

Biotechnology

Healthcare
$20.30 -2.34%

-$1.13 today

Market cap
$1.42B
Beta
1.00
P/E (TTM)
-14.1
EPS (TTM)
-$3.33
52W Low $8.73High $71.50

Volume 1.13M

Average 1.75M

QURE Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

uniQure N.V.NASDAQ: QURE

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 93.9%

Gross margin was 93.9% in Q1 FY2026, up 6.4 pp from a year earlier. On a trailing-twelve-month basis it was 74.1%, up 20.2 pp year over year. Over 3 fiscal years it narrowed by 7.3 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
93.9%+55.0 pp QoQ
Last fiscal yearDec 2025
89.5%+57.1 pp YoY
LTMMar 2026
74.1%+20.2 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+6.4 pp——
1 year+57.1 pp——
3 years-7.3 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
89.5%
Year-over-year change
+57.1pp

Gross Margin vs competitors

How QURE compares with its peers on the latest reported figures

  • QURE's LTM Mar 2026 gross margin of 74.1% is the 3rd highest of the 6 companies compared; the peer median is -0.1%.
  • Its year-over-year change of +20.2 pp is the 3rd highest of 6, against a peer median of +2.3 pp.
  • Over three fiscal years its change of -7.3 pp compares with a peer median of +36.5 pp.
QURE Competitors Peer median
Gross Margin for QURE and competitors
Company Period LTM level YoY 3-year change
MGTXMeiraGTx Holdings plcLTM Mar 202691.6% +64.6 pp-6.0 pp
RAREUltragenyx Pharmaceutical Inc.LTM Mar 202683.6% -1.6 pp-8.4 pp
QUREuniQure N.V.LTM Mar 202674.1% +20.2 pp-7.3 pp
RGNXREGENXBIO Inc.LTM Mar 2026-0.1% -76.7 pp+36.5 pp
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-12.4% +490439.7 pp+2555.9 pp
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-86.7% +2.3 pp+136.3 pp
NGNENeurogene Inc.FY2025— ——
RCKTRocket Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding QURE) -0.1%+2.3 pp+36.5 pp

Competitors are the stored peer set for QURE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue524M106.48M15.84M27.12M16.1M
Cost of Revenue24.98M3.34M13.63M18.33M1.69M
Gross Profit499.03M103.14M2.22M8.79M14.41M
Gross Margin95.2%96.9%14.0%32.4%89.5%
Research & Development143.55M197.59M214.86M143.78M140.67M
Selling, General & Admin56.29M54.7M73.08M50.68M65.34M
Operating Expenses188.41M246.3M285.09M193.09M202.24M
Depreciation & Amortization7.3M8.54M11.9M12.64M14.76M
EBITDA319M(108.02M)(253.1M)(160.75M)(116.59M)
EBITDA Margin60.9%-101.4%-1597.6%-592.7%-724.2%
Operating Income310.62M(143.16M)(282.87M)(184.29M)(187.83M)
Operating Margin59.3%-134.4%-1785.5%-679.6%-1166.8%
Interest Income162K609K19.56M21.42M16.97M
Interest Expense7.47M11.7M41.56M63.74M61.99M
Other Income / Expenses22.19M14.9M(23.69M)(52.83M)(5.51M)
Income Before Tax332.81M(128.26M)(306.56M)(237.13M)(193.34M)
Pre-Tax Margin63.5%-120.5%-1935.0%-874.4%-1201.0%
Income Tax Expense3.22M(1.47M)1.92M2.43M5.63M
Net Income329.59M(126.79M)(308.48M)(239.56M)(198.97M)
Net Margin62.9%-119.1%-1947.1%-883.4%-1236.0%
EPS (Basic)7.17(2.71)(6.47)(4.92)(3.46)
EPS (Diluted)7.04(2.71)(6.47)(4.92)(3.46)
Weighted Avg Shares45.99M46.74M47.67M48.65M57.5M
Weighted Avg Shares (Diluted)46.84M46.74M47.67M48.65M57.5M

uniQure N.V.

NASDAQ:QURE

Intrinsic Alpha fair value

Locked

Current Price

$20.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.